Bimatoprost
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Bimatoprost
- Pharmacist Assessment Report
- Bimatoprost: Prostamide F2-alpha analog → malformation syndrome with odontal and/or periodontal component
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- India Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Bimatoprost: Prostamide F2-alpha analog → malformation syndrome with odontal and/or periodontal component
One-Sentence Summary
Bimatoprost is a prostamide F2-alpha analog applied as an eye drop and marketed in India under multiple licences. The TxGNN model ranks malformation syndrome with odontal and/or periodontal component first among its predictions, with a score of 0.9999. There are currently no clinical trials and no publications supporting this prediction, so it rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | malformation syndrome with odontal and/or periodontal component |
| TxGNN Prediction Score | 0.9999 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Bimatoprost is known as a prostamide F2-alpha analog that acts on prostanoid FP/prostamide receptor signalling and prolongs the hair growth (anagen) phase.
No plausible pathway links this mechanism to a dental or periodontal malformation syndrome. Such syndromes are congenital structural conditions, and a topical eye-drop prostamide is not expected to alter them. The high score is a model-based prediction only, with no supporting trial or literature evidence, so the prediction should be treated as a hypothesis with no demonstrated rationale.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 94471 | Ganfort Eye Drop | packet of 3 ml Eye Drop | Not recorded |
| 30237 | Bimaton 0.03% Eye Drop | bottle of 3 ml Eye Drop | Not recorded |
| 26597 | Bimapix 0.01% Eye Drop | bottle of 3 ml Eye Drop | Not recorded |
| 26087 | Bimat Eye Drop | packet of 3 ml Ophthalmic Solution | Not recorded |
| 26873 | Bimaday Eye Drop | packet of 3 ml Ophthalmic Solution | Not recorded |
The list shows five of the 20 valid licences and may be partial.
Safety Considerations
- Drug Interactions: 66 potential interactions were identified in the interaction databases, all with an unspecified severity level. Examples include prednisone, prednisolone, triamcinolone, metformin, simvastatin, omeprazole and morphine.
Please refer to the package insert for further safety information on warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no clinical or literature support and no identifiable mechanistic link, so it cannot be advanced on the basis of the model score alone.
To proceed, the following is needed:
- A plausible mechanistic hypothesis connecting bimatoprost to dental or periodontal malformation syndromes
- Preclinical or clinical studies that directly address this disease
- Package insert warnings and contraindications for safety screening
- Detailed mechanism of action data
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.